Bosutinib

伯舒替尼

Report date: 2023/03/24 15:14:13
NME

Base Information

Drug NameBosutinib
Drug Alias Name博舒替尼BosutinibumBosutinib Monohydrate柏舒替尼波舒替尼 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsTyrosine-protein kinase Lyn inhibitorsBcr-Abl tyrosine kinase inhibitors +[4] 
TargetsTyrosine-protein kinase SRCTyrosine-protein kinase LynTyrosine-protein kinase HCK +[4] 
Therapy Area/IndicationsCognitive DysfunctionPhiladelphia ChromosomeBone Marrow Diseases +[22] 
Global Approved IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, Accelerated PhaseBlast Crisis +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/09/04
Country/TerritoryCzechiaBelgiumCanada +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesGeorgetown UniversityPfizer IncKyoto University +[5] 
Inactive CompaniesWyeth LlcUniversity Of California San FranciscoUniversity Of Milano Bicocca +[7] 
Active IndicationsCognitive DysfunctionAmyotrophic Lateral SclerosisDementia +[8] 
Inactive IndicationsPhiladelphia ChromosomeBone Marrow DiseasesKidney Failure, Chronic +[14] 

Other Information

ATC CodeL01EA04
Related LinksWikipediaDrugBankKEGG